Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | President, R&D | March 06, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 06, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,473 |
Reported balance
After 2023-03-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-06 · Purchase · Acquired 3,000 · Balance 11,473 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended. |
| Common StockSEC Table I · non-derivative | Direct | 13,473 |
Reported balance
After 2023-03-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-07 · Purchase · Acquired 2,000 · Balance 13,473 F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 14,473 |
Reported balance
After 2023-03-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-10 · Purchase · Acquired 1,000 · Balance 14,473 F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 20,771 |
Reported balance
After 2023-03-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-03-10 · Exercise / conversion · Acquired 6,298 · Balance 20,771 F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 18,339 |
Reported balance
After 2023-03-10 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2023-03-10 · Tax withholding · Disposed 2,432 · Balance 18,339 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,596 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Exercise / conversion · Disposed 6,298 · Balance 12,596 F6: Each RSU represents a contingent right to receive one share of the Company common stock. F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F6: Each RSU represents a contingent right to receive one share of the Company common stock.
F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 170 | $145.83 | $24,791.93 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.53 to $146.19, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 162 | $144.36 | $23,386.32 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.21 to $144.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 298 | $143.62 | $42,798.94 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,143 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.14 to $144.06, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 586 | $142.12 | $83,281.97 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,441 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.74 to $142.53, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,018 | $141.23 | $143,769.80 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,027 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.71 to $141.62, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 89 | $140.04 | $12,463.50 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,045 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.64 to $140.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 62 | $138.29 | $8,573.98 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,134 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.27 to $138.30, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Appreciation Right · Derivative | 4,819 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · derivative · entry 22 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,824 Underlying: Common Stock · 4,819 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · kind: The reporting person received 2,385 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 205 shares of common stock underlying the stock appreciation rights representing the base value and 2,229 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on May 17, 2021 of $140.16. F16 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,124 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · derivative · entry 21 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,504 Underlying: Common Stock · 3,124 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,101 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · derivative · entry 20 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,120 Underlying: Common Stock · 1,101 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 868 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · derivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,869 Underlying: Common Stock · 868 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 619 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · derivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623 Underlying: Common Stock · 619 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · derivative.exercise_date: Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of Novavax, Inc.'s common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Novavax, Inc.'s common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 2,918 shares were cancelled. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,229 | $140.16 | $312,416.64 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,196 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · kind: The reporting person received 2,385 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 205 shares of common stock underlying the stock appreciation rights representing the base value and 2,229 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on May 17, 2021 of $140.16. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerCommon Stock | 205 | $140.16 | $28,732.80 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,425 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · kind: The reporting person received 2,385 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 205 shares of common stock underlying the stock appreciation rights representing the base value and 2,229 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on May 17, 2021 of $140.16. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,819 | $5.95 | $28,673.05 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · kind: The reporting person received 2,385 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 205 shares of common stock underlying the stock appreciation rights representing the base value and 2,229 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on May 17, 2021 of $140.16. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,364 | $135.06 | $454,352.60 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.6001 to $135.4601, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,348 | $133.10 | $179,414.08 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,175 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.00 to $133.1301, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,000 | $131.50 | $131,500.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,523 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,124 | $5.95 | $18,587.80 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,101 | $46.00 | $50,646.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 868 | $27.60 | $23,956.80 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 619 | $27.00 | $16,713.00 |
DisclosureSEC source: 0001209191-21-034071 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 494 | $224.50 | $110,904.78 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 27 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F22 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.61 to $226.70, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 356 | $221.67 | $78,914.77 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 26 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,305 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.19 to $221.98, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 437 | $220.57 | $96,390.23 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 25 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,661 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.99, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 81 | $219.17 | $17,753.13 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 24 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,098 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.00 to $219.965, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 153 | $218.48 | $33,427.73 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 23 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,179 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.00 to $218.99, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 284 | $217.22 | $61,690.62 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 22 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,332 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.95 to $217.77, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 417 | $216.11 | $90,117.24 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 21 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,616 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.81 to $216.77, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 134 | $215.01 | $28,811.92 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 20 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,033 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.64 to $215.56, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 61 | $213.79 | $13,041.36 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,167 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.32 to $213.86, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Appreciation Right · Derivative | 4,819 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · derivative · entry 32 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,643 Underlying: Common Stock · 4,819 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · kind: The reporting person received 2,417 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 142 shares of common stock underlying the stock appreciation rights representing the base value and 2,260 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on April 15, 2021 of $202.09. F27 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,124 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · derivative · entry 31 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,628 Underlying: Common Stock · 3,124 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F26 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,101 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · derivative · entry 30 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,221 Underlying: Common Stock · 1,101 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F25 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 868 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · derivative · entry 29 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,737 Underlying: Common Stock · 868 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F24 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 619 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · derivative · entry 28 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,242 Underlying: Common Stock · 619 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F23 · derivative.exercise_date: Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of Novavax, Inc.'s common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Novavax, Inc.'s common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 2,918 shares were cancelled. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,260 | $202.09 | $456,723.40 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,228 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · kind: The reporting person received 2,417 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 142 shares of common stock underlying the stock appreciation rights representing the base value and 2,260 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on April 15, 2021 of $202.09. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerCommon Stock | 142 | $202.09 | $28,696.78 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,488 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · kind: The reporting person received 2,417 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 142 shares of common stock underlying the stock appreciation rights representing the base value and 2,260 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on April 15, 2021 of $202.09. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,819 | $202.09 | $973,871.71 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · kind: The reporting person received 2,417 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 142 shares of common stock underlying the stock appreciation rights representing the base value and 2,260 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on April 15, 2021 of $202.09. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 127 | $206.82 | $26,266.15 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.66 to $207.01, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 83 | $205.69 | $17,072.57 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,938 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.66 to $205.81, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 152 | $204.71 | $31,116.35 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.51 to $205.00, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 391 | $204.01 | $79,767.17 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,173 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.49 to $204.48, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 412 | $202.85 | $83,573.75 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,564 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.44 to $203.245, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 833 | $201.93 | $168,207.77 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,976 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.44 to $202.43, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 605 | $200.77 | $121,464.22 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,809 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.39 to $201.34, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 959 | $199.86 | $191,669.86 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,414 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.265 to $200.22, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 717 | $198.70 | $142,465.03 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,373 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.22 to $199.18, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 873 | $197.70 | $172,594.11 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,090 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.21 to $198.20, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:24 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 560 | $196.77 | $110,190.42 |
DisclosureSEC source: 0001209191-21-027469 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,963 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.19 to $197.12, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.